USFDA Approves BridgeBio's Welgemda as First Treatment for Rare Muscle Disease

Bengaluru: The US Food and Drug Administration said on Monday it has approved BridgeBio Pharma's drug for a type of rare inherited muscle disease, making it the first treatment to get the health regulator's approval for the condition.

The oral drug BBP-418, branded as Welgemda, will be used to treat patients with a form of limb-girdle muscular dystrophy, or LGMD, a group of inherited genetic disorders characterized by progressive muscle weakness and wasting.

Also Read - Nurokind-LC, Shelcal-500 Among Fake Drugs Seized in UP Counterfeit Medicine Racket, Key Accused Held

The disease primarily weakens the hip and shoulder muscles, making it difficult to climb stairs, run, lift the arms, or avoid falls, with some subtypes affecting breathing or heart function.

LGMD is the fourth most common muscular dystrophy with a prevalence of 1.63 per 100,000 individuals, according to National Institutes of Health data.

Shares of California-based BridgeBio were halted in afternoon trading.

News Source:

https://medicaldialogues.in/news/industry/pharma/usfda-approves-bridgebios-welgemda-as-first-treatment-for-rare-muscle-disease-183904?utm_campaign=&utm_content=ZINCOVIT%20vs%20ZINCOMED%3A%20Apex%20Labs%20Secures%20Madras%20HC%20Interim%20Injunction&utm_medium=email&utm_source=Newsletter&utm_term=